Senores Pharmaceuticals Ltd

Senores Pharmaceuticals Ltd

Senores Pharmaceuticals Ltd has submitted a statement of deviation or variation in the utilization of funds raised through a preferential issue of convertible equity warrants for the quarter ended June 30, 2026, stating that there has been no deviation or variation in the utilization of funds for the objects stated in the explanatory statement to the Notice of the Extra-ordinary General Meeting held on January 31, 2026.

Senores Pharmaceuticals Ltd

Senores Pharmaceuticals Ltd has submitted a statement of deviation or variation in utilisation of funds of public issue for the quarter ended June 30, 2026, indicating no deviation or variation in the utilization of proceeds of IPO.

Senores Pharmaceuticals Ltd

Senores Pharmaceuticals Ltd has submitted a Monitoring Agency Report for the quarter ended June 30, 2026, as per SEBI regulations, detailing the utilization of IPO proceeds.

Senores Pharmaceuticals Ltd

Senores Pharmaceuticals Ltd has released its Q1FY27 investor presentation, highlighting a 36% YoY revenue growth, 87% YoY EBITDA growth, and a 800 bps margin expansion. The company has also scaled up its owned ANDAs and corresponding ANDA products, with a robust pipeline of 39 molecules and 119 unique strengths.

Senores Pharmaceuticals Ltd

Senores Pharmaceuticals Limited announced its unaudited financial results for Q1 FY27, with revenue growing by 36% Y-o-Y, EBIDTA growing by 87% with a margin expansion of ~800 bps, and PAT growing by 56% Y-o-Y. The company reported strong growth across its businesses, with Regulated Markets revenue growing by 42% Y-o-Y and Emerging Markets revenue growing by 30% Y-o-Y. Senores also announced the addition of a USFDA-approved manufacturing plant in Baroda, which will enhance scalability, deepen access to Regulated Markets, and improve operating leverage and margins.

Senores Pharmaceuticals Ltd

Senores Pharmaceuticals Ltd has informed the exchange about the appointment of Ms. Anjali Shah as Assistant Vice President - Finance, categorized as Senior Management Personnel (SMP) of the Company, effective from July 27, 2026.

Senores Pharmaceuticals Ltd

Senores Pharmaceuticals Ltd has informed the exchange regarding Financial Results for quarter ended June 30, 2026, along with the Limited Review Report and auditor's report.

Senores Pharmaceuticals Ltd

Senores Pharmaceuticals Ltd has informed the exchange about the outcome of its board meeting held on July 27, 2026, where it announced unaudited consolidated and standalone financial results for the quarter ended June 30, 2026, along with the limited review report of its statutory auditors. The company also approved the appointment and categorization of Ms. Anjali Shah as Senior Management Personnel.

Senores Pharmaceuticals Ltd

Senores Pharmaceuticals Ltd has informed the Exchange regarding Earnings Conference Call for Q1FY27 scheduled to be held on July 27, 2026 at 05:15 P.M. (IST)

Senores Pharmaceuticals Ltd

Senores Pharmaceuticals Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 27/07/2026 to consider and approve the unaudited consolidated and standalone financial results for the quarter ended June 30, 2026.